AZN Stock Recent News
AZN LATEST HEADLINES
AstraZeneca PLC (LSE:AZN) shares opened lower on Wednesday after a late-stage trial of its experimental treatment for AL amyloidosis failed to meet its primary target in the overall patient group. The CARES phase III study tested anselamimab, a drug designed to clear harmful protein deposits in organs.
AstraZeneca on Wednesday said that its experimental drug anselamimab did not meet the main goal of a late-stage study for the treatment of AL amyloidosis, a rare condition that causes a buildup of protein deposits in the body.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Baxdostat trials showed immense promise for huge available market.
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) compared with placebo at 12 weeks. The trial also successfully met all secondary endpoints. Patients with uncontrolled or treatment resistant hypertension received baxdrostat or placebo on top of standard of care. Baxdrostat was generall.
AstraZeneca 's experimental drug baxdrostat has been successful in lowering high blood pressure in a late-stage study of people whose condition was hard to control or treat, the Anglo-Swedish drugmaker said on Monday, sending shares up 2%.
Shares in AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) were both down over 1% on Friday, but the shares are worth buying, analysts at Shore Capital said. Blue-chip shares across London and Europe were lower on Friday, after Donald Trump scaled up his tariff rhetoric again.
UBS has flagged a fresh risk for European drugmakers after President Trump said pharmaceuticals imported into the US could soon face tariffs of up to 200%. The comments, made earlier this week, revive concerns over protectionist policies targeting medicines not manufactured on American soil.